StockWatch
·
Q1 FY-2027 RESULTS · GPTHEALTH

GPT Healthcare Q1FY27: standalone PAT +65.7% YoY on margin expansion, revenue up 17.8%

PAT +65.74% YoY · revenue +17.83% · margins expanding

Q1 FY27 resultsGPTHEALTHGPT Healthcare Ltd03 Aug 2026 · 3 min read
Revenue

₹126.2 Cr

+17.83% YoY

PAT (standalone)

₹12.73 Cr

+65.74% YoY

Net margin

9.93%

+2.9pp YoY

EPS

₹1.55

GPT Healthcare's standalone revenue from operations rose 17.8% YoY to ₹126.20 Cr (Q1FY26: ₹107.11 Cr), while PAT climbed 65.7% YoY to ₹12.73 Cr (Q1FY26: ₹7.68 Cr) on basic EPS of ₹1.55 versus ₹0.94. Sequentially revenue was flat (-0.1% QoQ vs ₹126.37 Cr in Q4FY26), but PAT fell 12.6% QoQ from ₹14.57 Cr — a tax-driven dip, not an operating one: PBT actually grew 8.2% QoQ to ₹17.16 Cr, but Q4FY26's effective tax rate was an unusually low ~8.2% (helped by a ~₹3.50 Cr deferred-tax credit) against this quarter's normalized ~25.8% rate.

The scoreboard

Q1 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹126.2 Cr-0.1%+17.8%
Expenses₹111.07 Cr-1%+13.8%
PAT₹12.73 Cr-12.6%+65.74%
Net margin9.93%-1.5pp+2.9pp
EPS₹1.55-12.9%+64.9%

Operating margin (EBITDA/revenue, computed as PBT less other income plus depreciation and finance costs, over revenue) expanded to 19.16% from 16.21% a year ago and 18.49% last quarter, pointing to genuine operating leverage as cost lines (materials, employee expense) grew slower than revenue. Net margin (PAT/total income) improved YoY to 9.93% from 7.07%, though it read lower than Q4FY26's 11.38% purely because of the tax-base effect described above.

₹
134.58144.52154.46164.4174.34163.0404-3005-2206-1607-0907-3108-03Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹163.04, up 2.7% over the past month of trading.

₹ Cr
05.4410.8816.3112.89Q4 FY25rev ₹101 Cr7.68Q1 FY26rev ₹107 Cr10.6Q2 FY26rev ₹119 Cr9.37Q3 FY26rev ₹120 Cr14.57Q4 FY26rev ₹126 Cr12.73Q1 FY27rev ₹126 Cr
Quarterly standalone PAT, ₹ Crore
What management guided (4 FY-2026 call)
GPT Healthcare projects a 15% year-on-year revenue increase for FY27, driven by an expected 8% growth in ARPOB through tariff increases and specialty optimization. The company anticipates reaching approximately 20.2% EBITDA margin for FY27, with the newly commissioned Raipur hospital expected to break even on a monthly

— This quarter: met

Management's FY27 guidance (from the Q4FY26 concall) called for 15% YoY revenue growth, ~8% ARPOB growth, and a step-up to ~20.2% EBITDA margin for the full year, alongside Raipur hospital reaching monthly breakeven by Q3FY27 (~30% occupancy by year-end) and a ~150-bed Jamshedpur addition by Q4FY27. Q1's 17.8% YoY revenue growth already runs ahead of the 15% annual guidance pace, and the 19.16% OPM is progressing toward, though still short of, the 20.2% full-year target — consistent with management's own outlook rather than contradicting it. The filing discloses only one reportable segment (healthcare services in India, Note 3), so hospital-level Raipur/Jamshedpur progress cannot be independently verified from these numbers. No management press release was available in the context to cross-check messaging, and no broker/consensus estimates for this quarter could be located in a web search, so the print cannot be benchmarked against street numbers this quarter. Corporate developments this quarter were administrative — the board approved results at today's meeting, following the trading-window closure on June 27 and the July 9 dispatch of the AGM notice along with a ₹1.50/share final FY26 dividend — none of which bear on the operating print.

  • W1

    FY27 OPM trajectory toward management's 20.2% guided EBITDA margin — currently 19.16% in Q1, up from 18.49% in Q4FY26

  • W2

    Raipur hospital: management guided monthly breakeven by Q3FY27 and ~30% occupancy by FY27-end — no hospital-level disclosure yet to verify progress

  • W3

    Jamshedpur expansion (~150 beds) targeted for Q4FY27 — watch for commissioning updates and associated capex

Informational and educational content only. Not investment advice.